ADMA Bio reports Q2 2026 results with 24% revenue growth for ASCENIV
ADMA Bio reported Q2 2026 financial results, showing strong growth in ASCENIV revenue and GAAP net income. The company reiterated FY2026 guidance and announced real-world evidence highlighting clinical improvements in treated patients.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day